Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 16, 2007, Pages 4464-4470

  Poitout, Lydie ^a   Brault, Valérie ^a   Sackur, Carole ^a   Bernetière, Sonia ^a   Camara, José ^a   Plas, Pascale ^a   Roubert, Pierre ^a  

^a Institut Henri Beaufour   (France)

Author keywords

Antagonist; Benzimidazole; Melanocortin 4 receptor

Indexed keywords

BENZAMIDINE; BENZIMIDAZOLE DERIVATIVE; MCL 0129; MELANOCORTIN 4 RECEPTOR; ML 253764; PIPERAZINEBENZYLAMINE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CACHEXIA; CHEMICAL REACTION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; LIGAND BINDING; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; AREA UNDER CURVE; BENZIMIDAZOLES; BLOOD-BRAIN BARRIER; BRAIN; HALF-LIFE; HUMANS; MOLECULAR STRUCTURE; RATS; RECEPTOR, MELANOCORTIN, TYPE 4; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 34447310285     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.06.010     Document Type: Article

References (22)

1. Wikberg J.E.S. Eur. J. Pharmacol. 375 (1999) 295
2. Irani B.G., and Haskell-Luevano C. Peptides 26 (2005) 1788
3. Tisdale M.J. J. Natl. Cancer Inst. 89 (1997) 1763
4. Foster A.C., Chen C., Markison S., and Marks D.L. IDrugs 8 (2005) 314
5. Scarlett J.M., and Marks D.L. Expert Opin. Investig. Drugs 14 (2005) 1233
6. Chaki S., Hirota S., Funakoshi T., Suzuki Y., Suetake S., Okubo T., Ishii T., Nakazato A., and Okuyama S.J. Pharmacol. Exp. Ther. 304 (2003) 818
7. Vos T.J., Caracoti A., Che J., Dai M., Farrer C.A., Forsyth N.E., Drabic S.V., Horlick R.A., Lamppu D., Yowe D.L., Balani S., Li P., Zeng H., Joseph I.B.J.K., Rodriguez L.E., Maguire M.P., Patane M.A., and Claiborne C.F. J. Med. Chem. 47 (2004) 1602
8. Marsilje T.H., Roses J.B., Calderwood E.F., Stroud S.G., Forsyth N.E., Blackburn C., Yowe D.L., Miao W., Drabic S.V., Bohane M.D., Daniels J.S., Li P., Wu L., Patane M.A., and Claiborne C.F. Bioorg. Med. Chem. Lett. 14 (2004) 3721
9. Pontillo J., Tran J.A., Markison S., Joppa M., Fleck B.A., Marinkovic D., Arellano M., Tucci F.C., Lanier M., Nelson J., Saunders J., Hoare S.R.J., and Foster A.C.C. Bioorg. Med. Chem. Lett. 15 (2005) 2541
10. Tucci F.C., White N.S., Markison S., Joppa M., Tran J.A., Fleck B.A., Madan A., Dyck B.P., Parker J., Pontillo J., Arellano M., Marinkovic D., Wanlong J., Chen C.W., Gogas K.R., Goodfellow V.S., Saunders J., Foster C.A., and Chen C. Bioorg. Med. Chem. Lett. 15 (2005) 4389
11. Markison S., Foster A.C., Chen C., Brookhart G.B., Hesse A., Hoare S.R.J., Fleck B.A., Brown B.T., and Marks D.L. Endocrinology 146 (2005) 2766
12. Chen C.W., Tran J.A., Jiang W., Tucci F.C., Arellano M., Wen J., Fleck B.A., Marinkovic D., White N.S., Pontillo J., Saunders J., Madan A., Foster A.C., and Chen C. Bioorg. Med. Chem. Lett. 16 (2006) 4800
13. 125I]NDP-α-MSH was separated by filtration through GF/C glass fibre filters presoaked with 0.1% (w/v) PEI. Filters were washed three times with 50 mM Tris-HCl, pH 7.4, at 0-4 °C and assayed for radioactivity using Perkin-Elmer Topcount counter. Binding data were analysed by computer-assisted non-linear regression analysis (XL fit; IDBS).
14. Schmelkes F.C., and Rubin M. J. Am. Chem. Soc. 66 (1944) 1631
15. Howes P.D., Cleasby A., Evans D.N., Feilden H., Smith P.W., Sollis S.L., Taylor N., and Wonacott A.J. Eur. J. Med. Chem. 34 (1999) 225
16. Mohsen A., Omar M.E., Habib N.S., and Abouluafa O.M. Synthesis (1977) 864
17. ®) was used instead of N,N′-dicyclohexylcarbodimide to facilitate by-products removal.
18. Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx M., and Janssen P.A.J. J. Med. Chem. 28 (1985) 1925
19. Yadagiri B., and Lown J.W. Synth. Commun. 20 (1990) 955
20. Nestor J.J., Horner B.L., Jones G.H., McRae G.I., and Vickery B.H. J. Med. Chem. 27 (1984) 320
21. Cyclic AMP assay: Intracellular cyclic AMP (cAMP) levels were determined by an electro-chemiluminescence (ECL) assay (Meso Scale Discovery, MSD). CHO-K1 cells stably expressing the human MC4 receptors were suspended in RMPI 1640 containing 0.5 mM IBMX and 0.2% protein cocktail (MSD). They were dispensed (7000 cells/well) in multi-array plates containing integrated carbon electrodes and coated with anti-cAMP antibody. Concentration-response experiments of NDP-α-MSH were carried out in the presence of increasing concentrations of the tested compound by incubating the cells for 40 min at 37 °C. Then, the cells were lysed and 2.5 nM TAG ruthenium-labelled cAMP was added. After 90 min, cAMP levels were determined by ECL detection using sector imager 6000 reader (MSD). cAMP data were analysed by computer-assisted non-linear regression analysis (XL fit; IDBS). The Kb values were determined by Schild regression analysis.
22. Fed male Sprague-Dawley rats were dosed in groups of three animals (for each kinetic point). A solution of 4.5 μmol/kg in 1 ml/kg of a 10% DMA/90% propanediol solution was given by intravenous administration via the penile vein. Then, rats were deeply anaesthetised under Isoflurane® and blood was taken from the vena cava (at 1, 15, 30, 60, 90 and 120 min) and centrifuged (2000g, 15 min, 4 °C). The supernatants were mixed with cold acetonitrile to precipitate the proteins. After a further centrifugation (2000g, 15 min, 4 °C), the samples were analysed by HPLC (UV detection) or frozen at - 80° pending analysis. After blood withdrawal, tissues were rapidly washed by intracardiac perfusion with 50 ml of saline. The brains were then removed, frozen in liquid nitrogen and weighed. After mixing the brains with methanol for 40 s with an Ultraturax®, brain homogenates were centrifuged (25,000g, 15 min, 4 °C) and the supernatants were analysed by HPLC.